Table 1.
Stage-2 HAT severity assessment chart.
Fig 1.
Yearly admissions of study subjects and treatment regimens over the study period.
Arrows indicate introduction of select treatment regimens. Plain line = 4 successive regimens (ARS9 or melaroprol long schedule, ARS10 or short schedule melarsoprol, DFMO B or first-line eflornithine and NECT or nifurtimox-eflornithine combination therapy). Dotted line = period when severely affected patients were exceptionally treated with eflornithine (DFMO A), which was the preferred option for relapsed cases. Peaks in admissions correspond to the discovery of new foci of sleeping sickness in the villages of Kimwenza in 2001 and Muwana in 2007.
Table 2.
Syndromic and functional aspects of clinical presentation in the 781 study subjects.
Table 3.
Frequency by severity grade in the 781 study subjects.
Table 4.
Socio-demographic, biological and clinical characteristics by treatment group.
Fig 2.
Yearly distribution of deaths and severely affected subjects on admission over the study period.
Plain line = number of deaths per year; dotted line = number of severe (dysfunctional) cases on admission per year.
Fig 3.
Proportion of deaths by severity grade on admission.
N = number of patients admitted in one severity grade group; n = number of deaths in the corresponding severity grade group. Bars = percentage of deaths in each grade group. Black bars and dashed bars represent deceased patients among those admitted in dysfunctional (severely affected) and non-dysfunctional states, respectively.
Fig 4.
Proportion of deaths by clinical status on admission by treatment.
Black bar = deceased, dysfunctional on admission; dashed bar = deceased, non-dysfunctional on admission.
Table 5.
Unadjusted odds of death.
Table 6.
Unadjusted odds of deaths by treatment group.
Table 7.
Adjusted odds of deaths by treatment group.